Arcus Biosciences Inc (NYSE: RCUS) is -19.84% lower on its value in year-to-date trading and has touched a low of $12.95 and a high of $20.31 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RCUS stock was last observed hovering at around $15.39 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $15.31, the stock is -5.51% and -4.87% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.76 million and changing -0.52% at the moment leaves the stock -7.06% off its SMA200. RCUS registered -10.26% loss for a year compared to 6-month loss of -11.35%. The firm has a 50-day simple moving average (SMA 50) of $16.1094 and a 200-day simple moving average (SMA200) of $16.4582.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -6.19% gain in the last 1 month and extending the period to 3 months gives it a 8.43%, and is -0.52% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.28% over the week and 4.64% over the month.
Arcus Biosciences Inc (RCUS) has around 577 employees, a market worth around $1.40B and $247.00M in sales. Profit margin for the company is -100.81%. Distance from 52-week low is 18.22% and -24.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-39.21%).
Arcus Biosciences Inc quarterly earnings per share for the current quarter are estimated at -0.89 with sales reaching $57.07M over the same period.The EPS is expected to grow by 27.18% this year, but quarterly earnings will post 128.30% year-over-year.
272.0 institutions hold shares in Arcus Biosciences Inc (RCUS), with institutional investors hold 98.81% of the company’s shares. The shares outstanding are 75.50M, and float is at 48.07M with Short Float at 14.35%. Institutions hold 58.65% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 9.76 million shares valued at $148.69 million. The investor’s holdings represent 11.3261 of the RCUS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 5.26 million shares valued at $80.07 million to account for 6.099 of the shares outstanding. The other top investors are WOODLINE PARTNERS LP which holds 4.25 million shares representing 4.9249 and valued at over $64.65 million, while FMR LLC holds 4.8501 of the shares totaling 4.18 million with a market value of $63.67 million.
Arcus Biosciences Inc (RCUS) Insider Activity
The most recent transaction is an insider sale by Azoy Alexander, the company’s Chief Accounting Officer. SEC filings show that Azoy Alexander sold 1,357 shares of the company’s common stock on Aug 13 ’24 at a price of $14.97 per share for a total of $20314.0. Following the sale, the insider now owns 19070.0 shares.
Arcus Biosciences Inc disclosed in a document filed with the SEC on Mar 27 ’24 that Jarrett Jennifer (Chief Operating Officer) sold a total of 11,551 shares of the company’s common stock. The trade occurred on Mar 27 ’24 and was made at $17.55 per share for $0.2 million. Following the transaction, the insider now directly holds 0.22 million shares of the RCUS stock.
Still, SEC filings show that on Mar 18 ’24, Jarrett Jennifer (Chief Operating Officer) disposed off 13,449 shares at an average price of $17.92 for $0.24 million. The insider now directly holds 226,804 shares of Arcus Biosciences Inc (RCUS).
